Cancer immunotherpay

September 19, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm https://genomediscovery.org/wp-content/uploads/2019/09/Palbociclib-Fulvestrant-functions-as-an-antitumor-agent-through-induction-of-TPM1-CADM1.2-and-others.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/Palbociclib-Fulvestrant-functions-as-an-antitumor-agent-through-induction-of-TPM1-CADM1.2-and-others.jpg September 19, 2019 September 19, 2019

Introduction: What they say A study from Institute of Cancer Research and Royal Marsden Hospital, London, David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, and Pfizer Oncology,…

February 28, 2019

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-GPC2Glypican-2-expression-and-enhances-the-efficacy-of-cancer-immuotherapy-in-Neuroblastoma.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-GPC2Glypican-2-expression-and-enhances-the-efficacy-of-cancer-immuotherapy-in-Neuroblastoma.jpg February 28, 2019 February 28, 2019

National Science day special ********* We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted today (28/February/2019) will be…

February 28, 2019

Combinatorial anti-cancer therapy targeting CDK4/6 pathway and immune receptors enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 28/February/2019, 7.39 am

Combinatorial anti-cancer therapy targeting CDK4/6 pathway and immune receptors enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 28/February/2019, 7.39 am https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxyd-glucose-MNDDG-inhibits-CDK4.6-expression-and-enhances-the-efficacy-of-cancer-immunotherapy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxyd-glucose-MNDDG-inhibits-CDK4.6-expression-and-enhances-the-efficacy-of-cancer-immunotherapy.jpg February 28, 2019 February 28, 2019

February 24, 2019

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG) inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG) inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-PTPN2-and-increases-the-efficacy-of-cancer-immunotherapy2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-PTPN2-and-increases-the-efficacy-of-cancer-immunotherapy2.jpg February 24, 2019 February 24, 2019

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts…

January 31, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing MiRNA-129 and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CADM1, BIRC5, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 31/January/2019, `10.44 pm https://genomediscovery.org/wp-content/uploads/2019/01/MiR-129-fns-as-an-anticancer-agent-through-induction-of-CADM1-and-BIRC5.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/01/MiR-129-fns-as-an-anticancer-agent-through-induction-of-CADM1-and-BIRC5.jpg January 31, 2019 January 31, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

November 5, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 6/November/2018, 12.27 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 6/November/2018, 12.27 am https://genomediscovery.org/wp-content/uploads/2018/11/Olaparib-and-Lactobacillus-rhamnosus-function-as-anti-tumor.metastasis-suppressors.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/11/Olaparib-and-Lactobacillus-rhamnosus-function-as-anti-tumor.metastasis-suppressors.jpg November 5, 2018 November 5, 2018

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e…

Popular Post